The feasibility of multiple units of convalescent plasma in mechanically ventilated patients with COVID-19: A pilot study.
作者信息
Merin Noah M, LeVee Alexis A, Merlo Christian A, Spector Kellie, Coleman Hannah, Klapper Ellen, Hayes Chelsea, Zabner Rachel, McDyer John F, Eby Yolanda J, Sullivan David J, Tobian Aaron A R, Bloch Evan M, Hager David N
机构信息
Department of Internal Medicine, Division of Hematology, Cedars-Sinai Medical Center, Los Angeles, USA.
Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, USA.
出版信息
Transfus Apher Sci. 2022 Aug;61(4):103423. doi: 10.1016/j.transci.2022.103423. Epub 2022 Mar 15.
Abstract
摘要
相似文献
1
The feasibility of multiple units of convalescent plasma in mechanically ventilated patients with COVID-19: A pilot study.新冠病毒肺炎机械通气患者使用多单位康复期血浆的可行性：一项初步研究。
Transfus Apher Sci. 2022 Aug;61(4):103423. doi: 10.1016/j.transci.2022.103423. Epub 2022 Mar 15.
2
A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.一项多中心随机试验，旨在评估恢复期血浆疗法在接受机械通气治疗的侵袭性 COVID-19 和急性呼吸衰竭患者中的疗效：CONFIDENT 试验方案。
BMC Pulm Med. 2020 Dec 7;20(1):317. doi: 10.1186/s12890-020-01361-x.
3
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.一项随机、多中心、开放性 II 期概念验证临床试验，旨在研究恢复期血浆联合 COVID-19 住院患者标准治疗的临床疗效和安全性：捐赠抗体对抗新型冠状病毒（DAWn-Plasma）试验。
Trials. 2020 Nov 27;21(1):981. doi: 10.1186/s13063-020-04876-0.
4
Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.中国武汉 COVID-19 恢复期血浆采集试点项目的可行性。
Transfusion. 2020 Aug;60(8):1773-1777. doi: 10.1111/trf.15921. Epub 2020 Jul 31.
5
[COVID-19: Still a place for the convalescent plasma? Focus on the immunocompromised patients].[新型冠状病毒肺炎：恢复期血浆疗法仍有应用空间？聚焦免疫功能低下患者]
Rev Med Interne. 2023 Sep;44(9):467-471. doi: 10.1016/j.revmed.2023.08.005. Epub 2023 Sep 7.
6
Convalescent plasma therapy for coronavirus infection: experience from MERS and application in COVID-19.恢复期血浆疗法治疗冠状病毒感染：MERS 的经验及其在 COVID-19 中的应用。
Hum Vaccin Immunother. 2020 Dec 1;16(12):2973-2979. doi: 10.1080/21645515.2020.1793712. Epub 2020 Sep 3.
7
Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States.美国新冠疫情演变阶段恢复期血浆采集面临的监管挑战
Transfusion. 2022 Feb;62(2):483-492. doi: 10.1111/trf.16751. Epub 2021 Dec 3.
8
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.SARS-CoV-2 肺炎患者接受高滴度恢复期血浆治疗的临床和实验室评估。
JCI Insight. 2021 Mar 22;6(6):143196. doi: 10.1172/jci.insight.143196.
9
COVID-19 convalescent plasma from Norwegian blood donors.来自挪威献血者的新冠康复期血浆。
Tidsskr Nor Laegeforen. 2022 Jun 13;142(9). doi: 10.4045/tidsskr.22.0057. Print 2022 Jun 14.
10
Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.病例报告：恢复期血浆治疗后逐步出现抗炎和抗SARS-CoV-2作用并实现完全临床康复
Front Immunol. 2021 Apr 21;12:613502. doi: 10.3389/fimmu.2021.613502. eCollection 2021.
引用本文的文献
1
Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients.COVID-19 恢复期血浆滴度变化及受者 SARS-CoV2 特异性体液免疫对住院患者生存的影响。
PLoS One. 2024 Oct 24;19(10):e0309449. doi: 10.1371/journal.pone.0309449. eCollection 2024.
本文引用的文献
1
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.恢复期血浆抗体水平与新冠死亡风险。
N Engl J Med. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13.
2
Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point-of-Care Testing.血清学 SARS-CoV-2 侧向流动检测在快速床边检测中的评估。
J Clin Microbiol. 2021 Jan 21;59(2). doi: 10.1128/JCM.02020-20.
3
Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers.五种市售血清学检测方法检测 SARS-CoV-2 抗体的性能比较及识别高中和抗体滴度个体。
J Clin Microbiol. 2021 Jan 21;59(2). doi: 10.1128/JCM.02257-20.
4
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.用恢复期血浆治疗 COVID-19：从过去的冠状病毒爆发中吸取的教训。
Clin Microbiol Infect. 2020 Oct;26(10):1436-1446. doi: 10.1016/j.cmi.2020.08.005. Epub 2020 Aug 11.
5
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.性别、年龄和住院情况会影响 COVID-19 恢复期血浆捐献者人群的抗体反应。
J Clin Invest. 2020 Nov 2;130(11):6141-6150. doi: 10.1172/JCI142004.
6
Deployment of convalescent plasma for the prevention and treatment of COVID-19.恢复期血浆在 COVID-19 预防和治疗中的应用。
J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745.
7
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.用于描述器官功能障碍/衰竭的序贯器官衰竭评估（SOFA）评分。代表欧洲重症监护医学学会脓毒症相关问题工作组。
Intensive Care Med. 1996 Jul;22(7):707-10. doi: 10.1007/BF01709751.
8
APACHE II: a severity of disease classification system.急性生理与慢性健康状况评分系统II：一种疾病严重程度分类系统。
Crit Care Med. 1985 Oct;13(10):818-29.
Zotero 插件